Cancer nanomedicines: closing the translational gap

Nanomedicines in cancer use nanometre-scale drug delivery systems (eg, liposomes, dendrimers, polymers, or inorganic particles) that can improve solubility and drug pharmacokinetic profiles, protect therapeutic payloads from premature degradation, enhance drug delivery to diseased tissue, and contro...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2014-12, Vol.384 (9961), p.2175-2176
Main Authors: Gabizon, Alberto, Bradbury, Michelle, Prabhakar, Uma, Zamboni, William, Libutti, Steven, Grodzinski, Piotr
Format: Article
Language:English
Subjects:
Antigens
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - pharmacokinetics
Atoms & subatomic particles
Cancer
Cancer therapies
Drug Delivery Systems
Drug Evaluation, Preclinical
Drug therapy
Humans
Internal Medicine
Legislation, Drug
Mortality
Nanomedicine
Nanoparticles
Neoplasms - drug therapy
Pharmaceuticals
Pharmacokinetics
Polymers
Precision Medicine
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nanomedicines in cancer use nanometre-scale drug delivery systems (eg, liposomes, dendrimers, polymers, or inorganic particles) that can improve solubility and drug pharmacokinetic profiles, protect therapeutic payloads from premature degradation, enhance drug delivery to diseased tissue, and control rates of drug release, often resulting in reduced toxicities. 2,3 They can also enhance transport across biological barriers and overcome drug-resistance mechanisms.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(14)61457-4